Therapeutic vaccination for the elimination of HPV16+ high-grade dysplasia: A phase I clinical trial of the DNA vaccine pNGVL4aCRTE6E7L2, administered via the TriGrid™ electroporation device

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.011

Kimberly Levinson , Rebecca Arend , Benjamin Matthews , Tullia Rushton , Alfonsus Adrian Harsono , Hao Wang , Sejong Bae , Darin Ostrander , Karen Horner , Ashish Solanki , Alexis Peay , Stephanie Clevenger , Anna Wilbanks , Angelica Therese Gales , Chien-Fu Hung , Y.C. Tsai , Bailee Dover , Jennah Moore , Peter Ketch , Kaitlyn Kincaid , Richard Roden

引用次数: 0

查看原文本刊更多论文

消除 HPV16+ 高级发育不良的治疗性疫苗接种：通过 TriGrid™ 电穿孔设备接种 DNA 疫苗 pNGVL4aCRTE6E7L2 的 I 期临床试验

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy